CryoCath maintained at outperform

RBC Capital Markets analyst Phil Nalbone kept CryoCath Technologies Inc. at outperform, speculative risk. The company's third-quarter results showed product revenue totaling $9.7 million, up 5.6% year over year but below RBC's estimate of $11.4 million. Net loss for the quarter was $8.4 million, or $0.22 per share, compared to the analyst's estimated net loss of $4.8 million, or $0.13 per share. Shares of the Montreal-based medical device company were down C$0.39 cents, or 10.26%, at C$2.71, on volume of 82,338 shares versus the three-month running average of 31,657 shares. (Toronto: CYT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.